INARI MEDICAL, INC.

(NARI)
  Report
Real-time Estimate Cboe BZX  -  05/24 03:27:45 pm EDT
60.50 USD   -3.22%
05/18INSIDER SELL : Inari Medical
MT
05/13Inari Medical Announces Launch of 2021 Ethos and Sustainability Report
AQ
05/12TRANSCRIPT : Inari Medical, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 10:40 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue

01/10/2022 | 04:01pm EDT

IRVINE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue.

Preliminary Fourth Quarter Highlights:

  • Preliminary unaudited revenue is expected to be between $82.8 and $83.3 million for the fourth quarter of 2021, up 14% sequentially and 71% year-over-year (at the midpoint of the range).
  • Preliminary unaudited revenue for the full year 2021 is expected to be between $276.6 and $277.1 million, up approximately 98% over the full year 2020.
  • Treated 7,700 patients, an increase of 1,000 procedures or 15% from 6,700 procedures completed in Q3.   Over 90% of overall procedures and sequential procedural growth came from non-COVID patients.
  • Ended 2021 with over 200 U.S. sales territories.

“Despite the challenging operating environment, we are pleased with our continued crisp execution, not only commercially but across all of our growth drivers,” said Bill Hoffman, CEO of Inari Medical. “Although we are humbled by the ongoing opportunity to help treat COVID patients suffering from VTE, we are particularly encouraged that the vast majority of both total procedures and growth during the quarter came from treating non-COVID patients. This core patient population remains our strategic focus. We are increasingly confident we are finding ways to systematically identify, triage, and successfully treat these patients.”

The preliminary unaudited revenue results described in this press release are estimates only and subject to revision until we report our full financial results for 2021 in our Annual Report on Form 10-K.

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company focused on developing innovative products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated fourth quarter and full year 2021 revenue and procedures, and are based on Inari’s current expectations, forecasts, and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2020, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

Investor Contact:

ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com 


Primary Logo

Source: Inari Medical, Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about INARI MEDICAL, INC.
05/18INSIDER SELL : Inari Medical
MT
05/13Inari Medical Announces Launch of 2021 Ethos and Sustainability Report
AQ
05/12TRANSCRIPT : Inari Medical, Inc. Presents at Bank of America 2022 Healthcare Conference, M..
CI
05/04INARI MEDICAL, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
05/04TRANSCRIPT : Inari Medical, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Earnings Flash (NARI) INARI MEDICAL Posts Q1 Revenue $86.8M, vs. Street Est of $83.6M
MT
05/04Inari Medical Reports First Quarter 2022 Financial Results
AQ
05/04Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2022
CI
05/04Inari Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03INARI MEDICAL, INC.(NASDAQGS : NARI) added to S&P 400
CI
More news
Analyst Recommendations on INARI MEDICAL, INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -39,1 M - -
Net cash 2022 316 M - -
P/E ratio 2022 -82,3x
Yield 2022 -
Capitalization 3 321 M 3 321 M -
EV / Sales 2022 8,22x
EV / Sales 2023 6,88x
Nbr of Employees 800
Free-Float 85,0%
Chart INARI MEDICAL, INC.
Duration : Period :
Inari Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INARI MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 62,51 $
Average target price 111,67 $
Spread / Average Target 78,6%
EPS Revisions
Managers and Directors
William H. Hoffman President, Chief Executive Officer & Director
Mitchell C. Hill Chief Financial Officer
Don B. Milder Chairman
Thomas Tu Chief Medical Officer
Tara Dunn VP-Clinical Affairs & Market Development
Sector and Competitors
1st jan.Capi. (M$)
INARI MEDICAL, INC.-31.51%3 321
NOVOCURE LIMITED2.66%8 061
MASIMO CORPORATION-51.39%7 899
GETINGE AB-29.36%7 739
SHOCKWAVE MEDICAL, INC.-7.16%5 926
PENUMBRA, INC.-50.41%5 369